SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.

SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study. Ann Hepatol. 2014 Mar-Apr;13(2):303-4 Authors: D'heygere F, George C, Habersetzer F, Tripathi D, Q Pan C, Giron JA, Schmitz M, Tatsch F PMID: 24558225 [PubMed - indexed for MEDLINE]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research